Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	100.64	105.76	113.45	102.29
Revenue Growth (YoY)	-13.01%	-6.78%	10.91%	-
Cost of Revenue	3.8	3.88	4.64	4.79
Gross Profit	96.84	101.87	108.81	97.5
Selling, General & Admin	73.48	73.62	75.82	71.61
Research & Development	12.94	12.02	13.78	16.69
Operating Expenses	86.41	85.64	89.6	88.29
Operating Income	10.43	16.23	19.21	9.2
Interest & Investment Income	1.55	1.55	1.04	0.73
Earnings From Equity Investments	-0.04	-0.04	-1.31	-0.25
Currency Exchange Gain (Loss)	-1.5	-1.5	-1.5	-4.9
Other Non Operating Income (Expenses)	4.9	6.95	-8.97	3.73
EBT Excluding Unusual Items	15.34	23.18	8.48	8.51
Gain (Loss) on Sale of Assets	-0.07	-0.07	-3.34	-
Other Unusual Items	0.1	0.1	1	0.9
Pretax Income	15.37	23.22	-76.97	9.41
Income Tax Expense	3.68	5.32	8.52	5.1
Earnings From Continuing Operations	11.7	17.9	-85.48	4.31
Minority Interest in Earnings	-4.45	-5.81	-7.45	-2.01
Net Income	7.25	12.09	-92.93	2.3
Net Income to Common	7.25	12.09	-92.93	2.3
Shares Outstanding (Basic)	86	85	66	64
Shares Outstanding (Diluted)	102	102	66	76
Shares Change (YoY)	44.36%	55.39%	-13.02%	-
EPS (Basic)	0.08	0.14	-1.41	0.04
EPS (Diluted)	0.04	0.05	-1.41	0.03
Free Cash Flow	-	-5.96	17.38	5.69
Free Cash Flow Per Share	-	-0.06	0.26	0.07
Gross Margin	96.23%	96.33%	95.91%	95.31%
Operating Margin	10.36%	15.35%	16.93%	9.00%
Profit Margin	7.21%	11.43%	-81.92%	2.25%
Free Cash Flow Margin	-	-5.63%	15.32%	5.56%
EBITDA	11.99	17.82	20.33	10.33
EBITDA Margin	11.91%	16.85%	17.92%	10.10%
D&A For EBITDA	1.56	1.59	1.11	1.13
EBIT	10.43	16.23	19.21	9.2
EBIT Margin	10.36%	15.35%	16.93%	9.00%
Effective Tax Rate	23.91%	22.91%	-	54.16%

Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q